Long-term efficacy and progression patterns of paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: results from a phase II NEOCRTEC1601 study.
{"title":"Long-term efficacy and progression patterns of paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: results from a phase II NEOCRTEC1601 study.","authors":"Jia-Di Wu, Zhi-Qiang Wang, Qiao-Qiao Li, Chao Ren, Sheng Huang, Cai-Yan Fang, De-Shen Wang, Ji-Yang Chen, Qiong Tan, Yu-Hong Li, Hong Yang","doi":"10.1097/JS9.0000000000002360","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The NEOCRTEC1601 trial aimed to evaluate the efficacy and safety of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) as induction chemotherapy for BR-ESCC. This study presented an updated 5-year analysis to further elucidate the impact of TPF chemotherapy followed by surgery.</p><p><strong>Method: </strong>This study was conducted as a single-center, phase II, clinical trial. Eligibility was extended to patients diagnosed with BR-ESCC, characterized by a primary tumor or bulky lymph nodes with potential invasion into adjacent organs. The treatment protocol commenced with TPF chemotherapy, followed by surgery if the tumor was deemed resectable, or by concurrent chemoradiation in cases where resection was not feasible. This updated report delineates the 5-year overall survival and progression-free survival rate.</p><p><strong>Result: </strong>Surgery was performed for 27 patients (57.4%), and R0 resection was confirmed in 25 patients (53.2%). Pathologic complete response was confirmed in four patients (8.5%). Following a minimum follow-up period exceeding 60 months for all patients, the total number of deaths was 31 (65.96%). The OS and PFS for the R0 group were significantly longer than the non-R0 group (median OS: 53.0 months vs. 13.9 months, HR 0.36, 95%CI 0.17-0.76, p = 0.0032; median PFS: 50.84 months vs. 5.42 months, HR 0.40, 95%CI 0.19-0.84, p = 0.0076). The 5-year OS rate was 50.0% (34.0%-73.4%) for the R0 group compared to 19.0% (7.9%-46.0%) for the non-R0 group (HR 0.36, 95%CI 0.17-0.79, p = 0.0041).</p><p><strong>Conclusion: </strong>Long-term follow-up evaluation confirmed that the OS and PFS were significantly improved in patients who underwent R0 resection compared to those who did not. The 5-year OS rate for patients who achieved R0 resection was 50.0%. R0 resection might be the independent prognostic factors for OS. To further improve the R0 resection rate and prognosis, more effective induction treatment regimens need to be explored.</p>","PeriodicalId":14401,"journal":{"name":"International journal of surgery","volume":" ","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JS9.0000000000002360","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The NEOCRTEC1601 trial aimed to evaluate the efficacy and safety of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) as induction chemotherapy for BR-ESCC. This study presented an updated 5-year analysis to further elucidate the impact of TPF chemotherapy followed by surgery.
Method: This study was conducted as a single-center, phase II, clinical trial. Eligibility was extended to patients diagnosed with BR-ESCC, characterized by a primary tumor or bulky lymph nodes with potential invasion into adjacent organs. The treatment protocol commenced with TPF chemotherapy, followed by surgery if the tumor was deemed resectable, or by concurrent chemoradiation in cases where resection was not feasible. This updated report delineates the 5-year overall survival and progression-free survival rate.
Result: Surgery was performed for 27 patients (57.4%), and R0 resection was confirmed in 25 patients (53.2%). Pathologic complete response was confirmed in four patients (8.5%). Following a minimum follow-up period exceeding 60 months for all patients, the total number of deaths was 31 (65.96%). The OS and PFS for the R0 group were significantly longer than the non-R0 group (median OS: 53.0 months vs. 13.9 months, HR 0.36, 95%CI 0.17-0.76, p = 0.0032; median PFS: 50.84 months vs. 5.42 months, HR 0.40, 95%CI 0.19-0.84, p = 0.0076). The 5-year OS rate was 50.0% (34.0%-73.4%) for the R0 group compared to 19.0% (7.9%-46.0%) for the non-R0 group (HR 0.36, 95%CI 0.17-0.79, p = 0.0041).
Conclusion: Long-term follow-up evaluation confirmed that the OS and PFS were significantly improved in patients who underwent R0 resection compared to those who did not. The 5-year OS rate for patients who achieved R0 resection was 50.0%. R0 resection might be the independent prognostic factors for OS. To further improve the R0 resection rate and prognosis, more effective induction treatment regimens need to be explored.
期刊介绍：
The International Journal of Surgery (IJS) has a broad scope, encompassing all surgical specialties. Its primary objective is to facilitate the exchange of crucial ideas and lines of thought between and across these specialties.By doing so, the journal aims to counter the growing trend of increasing sub-specialization, which can result in "tunnel-vision" and the isolation of significant surgical advancements within specific specialties.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
